More about

Ulcerative Colitis

Clinical Guidance
Ulcerative Colitis
Assessment and Treatment

Aminosalicylate Therapy

Gary R. Lichtenstein, MD, FACP, FACG, AGA; Robert B Stein, MD

Free clinical reference tool that includes treatment options; diagnosis information; guidelines; and more.

Clinical Guidance
Ulcerative Colitis
Presentation and Diagnosis

Diagnosis and Evaluation

Gary R. Lichtenstein, MD, FACP, FACG, AGA; Robert B Stein, MD

Free clinical reference tool that includes treatment options; diagnosis information; guidelines; and more.

Clinical Guidance
Ulcerative Colitis
Presentation and Diagnosis

Clinical Presentation

Gary R. Lichtenstein, MD, FACP, FACG, AGA; Robert B Stein, MD

Free clinical reference tool that includes treatment options; diagnosis information; guidelines; and more.

Clinical Guidance
Ulcerative Colitis
Overview

Environmental Risk and Protective Factors

Gary R. Lichtenstein, MD, FACP, FACG, AGA; Robert B Stein, MD

Free clinical reference tool that includes treatment options; diagnosis information; guidelines; and more.

Clinical Guidance
Ulcerative Colitis
Overview

Etiopathogenesis

Gary R. Lichtenstein, MD, FACP, FACG, AGA; Robert B Stein, MD

Free clinical reference tool that includes treatment options; diagnosis information; guidelines; and more.

Clinical Guidance
Ulcerative Colitis
Overview

Epidemiology

Gary R. Lichtenstein, MD, FACP, FACG, AGA; Robert B Stein, MD

Free clinical reference tool that includes treatment options; diagnosis information; guidelines; and more.

News
August 05, 2024
2 min read
Save

Vedolizumab improves clinical outcomes, induces mucosal healing in UC, chronic pouchitis

Vedolizumab improves clinical outcomes, induces mucosal healing in UC, chronic pouchitis

Vedolizumab not only induced endoscopic improvements in patients with chronic pouchitis, but also appeared to improve clinical outcomes at week 34, especially in those who achieved mucosal healing at week 14, research showed.

News
August 01, 2024
2 min read
Save

Skyrizi bests placebo in clinical remission as induction, maintenance therapy for UC

Skyrizi bests placebo in clinical remission as induction, maintenance therapy for UC

Skyrizi significantly improved clinical remission rates as both induction and maintenance therapy vs. placebo in patients with moderately to severely active ulcerative colitis, according to data from the phase 3 INSPIRE and COMMAND trials.

News
July 16, 2024
1 min read
Save

Higher adjusted AKI rate with inflammatory bowel disease vs. collagen vascular diseases

Higher adjusted AKI rate with inflammatory bowel disease vs. collagen vascular diseases

The frequency and risk of AKI in patients hospitalized with inflammatory bowel disease is higher compared with admissions with collagen vascular diseases and from the general population, a recently published study shows.

Clinical Guidance
Ankylosing Spondylitis
Overview

Etiology and Pathogenesis

Muhammad Asim Kahn, MD, FRCP, MACP; Nurullah Akkoç, MD

Free clinical reference tool that includes treatment options; diagnosis information; guidelines; and more.

View more